AU2018304208B2 - Methods of treating autoimmune microvascular disorders - Google Patents

Methods of treating autoimmune microvascular disorders Download PDF

Info

Publication number
AU2018304208B2
AU2018304208B2 AU2018304208A AU2018304208A AU2018304208B2 AU 2018304208 B2 AU2018304208 B2 AU 2018304208B2 AU 2018304208 A AU2018304208 A AU 2018304208A AU 2018304208 A AU2018304208 A AU 2018304208A AU 2018304208 B2 AU2018304208 B2 AU 2018304208B2
Authority
AU
Australia
Prior art keywords
subject
diosmin
pharmaceutically acceptable
therapeutically effective
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018304208A
Other languages
English (en)
Other versions
AU2018304208A1 (en
Inventor
Robert M. Levy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PRIMUS PHARMACEUTICALS Inc
Original Assignee
PRIMUS PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PRIMUS PHARMACEUTICALS Inc filed Critical PRIMUS PHARMACEUTICALS Inc
Publication of AU2018304208A1 publication Critical patent/AU2018304208A1/en
Application granted granted Critical
Publication of AU2018304208B2 publication Critical patent/AU2018304208B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018304208A 2017-07-19 2018-07-18 Methods of treating autoimmune microvascular disorders Active AU2018304208B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762534237P 2017-07-19 2017-07-19
US62/534,237 2017-07-19
PCT/US2018/042573 WO2019018455A1 (en) 2017-07-19 2018-07-18 METHODS OF TREATING AUTOIMMUNE MICROVASCULAR DISORDERS

Publications (2)

Publication Number Publication Date
AU2018304208A1 AU2018304208A1 (en) 2020-02-13
AU2018304208B2 true AU2018304208B2 (en) 2022-03-17

Family

ID=65016682

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018304208A Active AU2018304208B2 (en) 2017-07-19 2018-07-18 Methods of treating autoimmune microvascular disorders

Country Status (12)

Country Link
US (2) US11278517B2 (cg-RX-API-DMAC7.html)
EP (2) EP4269397A3 (cg-RX-API-DMAC7.html)
JP (1) JP7237962B2 (cg-RX-API-DMAC7.html)
KR (1) KR102717665B1 (cg-RX-API-DMAC7.html)
CN (1) CN111065389B (cg-RX-API-DMAC7.html)
AU (1) AU2018304208B2 (cg-RX-API-DMAC7.html)
CA (1) CA3069921C (cg-RX-API-DMAC7.html)
ES (1) ES2957742T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20231517T1 (cg-RX-API-DMAC7.html)
MX (1) MX2020000625A (cg-RX-API-DMAC7.html)
PL (1) PL3654965T3 (cg-RX-API-DMAC7.html)
WO (1) WO2019018455A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114306300A (zh) * 2022-01-04 2022-04-12 上海交通大学医学院附属仁济医院 一种香叶木素的用途及其动物模型的建立方法
KR20260010656A (ko) * 2024-07-11 2026-01-21 한국 한의학 연구원 한련초 추출물 유래 화합물을 유효성분으로 함유하는 천포창의 예방, 개선 또는 치료용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147054A (en) * 1996-11-29 2000-11-14 De Paoli Ambrosi; Gianfranco Composition for cosmetic, pharmaceutical or dietetic use based on an amino sugar and/or a polyhydroxylic acid
WO2015153648A1 (en) * 2014-03-31 2015-10-08 Ingredients By Nature Flavonoid compositions and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060100278A1 (en) 2002-08-20 2006-05-11 Cooper Garth J S Dosage forms and related therapies
FR2929276B1 (fr) 2008-04-01 2010-04-23 Servier Lab Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147054A (en) * 1996-11-29 2000-11-14 De Paoli Ambrosi; Gianfranco Composition for cosmetic, pharmaceutical or dietetic use based on an amino sugar and/or a polyhydroxylic acid
WO2015153648A1 (en) * 2014-03-31 2015-10-08 Ingredients By Nature Flavonoid compositions and uses thereof

Also Published As

Publication number Publication date
KR20200051579A (ko) 2020-05-13
EP3654965A4 (en) 2021-03-10
US11278517B2 (en) 2022-03-22
US20200147031A1 (en) 2020-05-14
EP3654965C0 (en) 2023-09-06
KR102717665B1 (ko) 2024-10-14
AU2018304208A1 (en) 2020-02-13
HRP20231517T1 (hr) 2024-03-01
CN111065389A (zh) 2020-04-24
US11844777B2 (en) 2023-12-19
CN111065389B (zh) 2023-11-21
JP7237962B2 (ja) 2023-03-13
MX2020000625A (es) 2020-09-28
CA3069921C (en) 2022-01-18
EP3654965A1 (en) 2020-05-27
JP2020528454A (ja) 2020-09-24
WO2019018455A1 (en) 2019-01-24
CA3069921A1 (en) 2019-01-24
PL3654965T3 (pl) 2024-02-26
US20220168267A1 (en) 2022-06-02
EP3654965B1 (en) 2023-09-06
ES2957742T3 (es) 2024-01-24
EP4269397A3 (en) 2024-01-31
EP4269397A2 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
Bounes et al. Is there an ideal morphine dose for prehospital treatment of severe acute pain? A randomized, double-blind comparison of 2 doses
AU2021209279B2 (en) Therapeutic uses of L-4-chlorokynurenine
Vitiello et al. An update on the treatment of the cutaneous manifestations of systemic sclerosis: the dermatologist's point of view
CA3075719A1 (en) Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults
KR20090034810A (ko) 멜라토닌 효능제 치료
MD3347002T2 (ro) Tratamentul bolii Alzheimer într-o populație specifică de pacienți
US11844777B2 (en) Methods of treating autoimmune microvascular disorders
Fischer et al. Efficacy and tolerability of ambroxol hydrochloride lozenges in sore throat
Schutz et al. Local anaesthetic properties of ambroxol hydrochloride lozenges in view of sore throat
JP5727642B2 (ja) センタキンを用いた新規の治療方法
EP4251164A2 (en) Treatment of raynaud's disease
US20260069578A1 (en) Treatment of neutrophilic dermatoses
KR100692235B1 (ko) 안지오텐신 ⅱ 길항물질의 신규한 용도
AU2005239799B2 (en) Sustained-release oral molsidomine composition for treating atherosclerosis
MX2013013124A (es) Combinaciones de trospio y estimulantes salivales para el tratamiento de la vejiga hiperactiva.
NEBIVOLOL Gender Differences/Issues P-477
HK1257800B (en) Therapeutic uses of l-4-chlorokynurenine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)